

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1-19. (Cancelled)

20. (Original) A method of screening for a compound for treating or preventing breast cancer, said method comprising the steps of:

- a) contacting a test compound with a polypeptide encoded by a polynucleotide selected from the group consisting of the genes of BRC Nos. 123-169, 171-449, and 451-512;
- b) detecting the binding activity between the polypeptide and the test compound; and
- c) selecting the test compound that binds to the polypeptide.

21-22. (Cancelled)

23. (Original) A method of screening for a compound for treating or preventing breast cancer, said method comprising the steps of:

- a) contacting a test compound with a polypeptide encoded by a polynucleotide selected from the group consisting of the genes of BRC Nos. 123-169, 171-449, and 451-512;
- b) detecting the biological activity of the polypeptide of step (a); and
- c) selecting the test compound that suppresses the biological activity of the polypeptide encoded by the polynucleotide selected from the group consisting of the genes of BRC Nos. 123-169, 171-175, 374-398, 448-449, and 451-471 as compared to the biological activity of said polypeptide detected in the absence of the test compound, or enhances the biological activity of the polypeptide encoded by the polynucleotide selected from the group consisting of the genes of BRC

Nos. 176-373, 399-447, and 472-512 as compared to the biological activity of said polypeptide detected in the absence of the test compound.

24. (Cancelled)

25. (Previously Presented) The method of claim 20, wherein said breast cancer is IDC, said method comprises the steps of:

- a) contacting a test compound with a polypeptide encoded by a polynucleotide selected from the group consisting of the genes of BRC Nos. 448-449 and 451-512;
- b) detecting the binding activity between the polypeptide and the test compound; and
- c) selecting the test compound that binds to the polypeptide.

26-27. (Cancelled)

28. (Previously Presented) The method of claim 23, wherein said breast cancer is IDC and said method comprises the steps of:

- a) contacting a test compound with a polypeptide encoded by a polynucleotide selected from the group consisting of the genes of BRC Nos. 448-449 and 451-512;
- b) detecting the biological activity of the polypeptide of step (a); and
- c) selecting the test compound that suppresses the biological activity of the polypeptide encoded by the polynucleotide selected from the group consisting of the genes of BRC Nos. 448-449 and 451-471, as compared to the biological activity of said polypeptide detected in the absence of the test compound, or enhances the biological activity of the polypeptide encoded by the polynucleotide selected from the group consisting of the genes of BRC Nos. 472-512 as compared to the biological activity of said polypeptide detected in the absence of the test compound.

29-59. (Cancelled)

60. (Original) A method of screening for a compound for treating or preventing invasion of breast cancer, said method comprising the steps of:

- a) contacting a test compound with a polypeptide encoded by a polynucleotide selected from the group consisting of the genes of BRC Nos. 374-447;
- b) detecting the binding activity between the polypeptide and the test compound; and
- c) selecting the test compound that binds to the polypeptide.

61-62. (Cancelled)

63. (Original) A method of screening for a compound for treating or preventing invasion of breast cancer, said method comprising the steps of:

- a) contacting a test compound with a polypeptide encoded by a polynucleotide selected from the group consisting of the genes of BRC Nos. 374-447;
- b) detecting the biological activity of the polypeptide of step (a); and
- c) selecting the test compound that suppresses the biological activity of the polypeptide encoded by the polynucleotide selected from the group consisting of the genes of BRC Nos. 374-398 as compared to the biological activity of said polypeptide detected in the absence of the test compound, or enhances the biological activity of the polypeptide encoded by the polynucleotide selected from the group consisting of the genes of BRC Nos. 399-447 as compared to the biological activity of said polypeptide detected in the absence of the test compound.

64-82. (cancelled)

83. (Original) A method of screening for a compound for treating breast cancer or preventing breast cancer metastasis, said method comprising the steps of:

- (1) contacting a test compound with a polypeptide encoded by a gene selected from the group consisting of genes of BRC Nos. 719-752:
- (2) detecting the binding activity between the polypeptide and the test compound; and

- (3) selecting the test compound that binds to the polypeptide.

84. (Original) A method of screening for a compound for treating breast cancer or preventing breast cancer metastasis, said method comprising the steps of:

- (1) contacting a test compound with a polypeptide encoded by a gene selected from the group consisting of genes of BRC Nos. 719-752;
- (2) detecting the biological activity of the polypeptide of step (a); and
- (3) selecting the test compound that reduces the biological activity of the polypeptide encoded by a gene selected from the group consisting of: VAMP3, MGC11257, GSPT1, DNMT2, CFL1, CLNS1A, SENP2, NDUFS3, NOP5/NOP58, PSMD13, SUOX, HRB2, LOC154467, THTPA, ZRF1, LOC51255, DEAF1, NEU1, UGCG1, BRAF, TUFM, FLJ10726, DNAJB1, AP4S1, and MRPL40 as compared to the biological activity detected in the absence of the test compound, or elevates the biological activity of the polypeptide encoded by a gene selected from the group consisting of: UBA52, GenBank Acc# AA634090, CEACAM3, C21orf97, KIAA1040, EEF1D, FUS, GenBank Acc# AW965200, and KIAA0475 as compared to the biological activity detected in the absence of the test compound.

85-97 (Cancelled)